Our Review Summary
This story is one of two we are reviewing that focuses on FDA’s approval of a drug designed to speed patient recovery from flu symptoms (the second story is from ABC News). The drug is baloxavir marboxil, marketed under the trade name Xofluza. This New York Times story hits most of the points that we want to see in a story about a new drug.
Why This Matters
The criteria that we use at HealthNewsReview.org to review health-related news stories were not developed in a vacuum. Rather, these are the criteria we feel are essential to allow patients and health care providers to make informed decisions about diagnosis and treatment options. While we do ding it on a couple things, the story does not exaggerate the findings, and provides people with the fundamental details they need to be informed patients.
We were especially pleased that this story did not perpetuate misinformation that’s developed around this drug — that is, that it could help reduce transmission of the virus. To date, there is no evidence to show that as a benefit.